 |
80 Diseases |  |
201 Trials |
|
201 Trials |  |
5515 News |  |
| «12...58596061626364656667686970» |
- Herceptin (trastuzumab) / Roche
New P1/2 trial: A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS (clinicaltrials.gov) - Jan 13, 2015
P1/2, N=15, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
- | Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, Combination therapy, Heterogeneity: T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA (clinicaltrials.gov) - Dec 30, 2014
P2, N=160, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Metastases: HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy (clinicaltrials.gov) - Dec 25, 2014
P=N/A, N=478, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2017 --> Sep 2018
- Perjeta (pertuzumab) / Roche
Trial completion date, Metastases: Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy (clinicaltrials.gov) - Dec 24, 2014
P2, N=60, Completed, Sponsor: Genentech, Inc.
Trial primary completion date: Mar 2017 --> Sep 2018 Trial completion date: Dec 2004 --> Apr 2005
- Perjeta (pertuzumab) / Roche
Trial completion date, Metastases: A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer (clinicaltrials.gov) - Dec 24, 2014
P2, N=129, Completed, Sponsor: Genentech, Inc.
Trial completion date: Dec 2004 --> Apr 2005 Trial completion date: Jun 2005 --> Jul 2004
- Perjeta (pertuzumab) / Roche
Trial completion date: Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Dec 24, 2014
P2, N=45, Completed, Sponsor: Genentech, Inc.
Trial completion date: Jun 2005 --> Jul 2004 Trial completion date: Jun 2004 --> Oct 2004
- ||| Biomarker, Enrollment change, MSi-H Biomarker, PD(L)-1 Biomarker, Metastases: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Dec 24, 2014
P2, N=610, Not yet recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Jun 2004 --> Oct 2004 N=1680 --> 610
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Metastases: Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer (clinicaltrials.gov) - Dec 19, 2014
P2, N=69, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
N=1680 --> 610 Trial primary completion date: Jan 2015 --> Jan 2016
- |||||||||| Perjeta (pertuzumab) / Roche
New P3 trial, Combination therapy: A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial (clinicaltrials.gov) - Dec 19, 2014
P3, N=250, Not yet recruiting, Sponsor: Hoffmann-La Roche
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, IO biomarker, Metastases: Vaccine Therapy in Treating Patients With Metastatic Solid Tumors (clinicaltrials.gov) - Dec 6, 2014
P1, N=36, Recruiting, Sponsor: Pravin Kaumaya
Trial primary completion date: Jan 2015 --> Jan 2016 Trial primary completion date: Oct 2014 --> Jan 2015
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Enrollment change, Trial primary completion date, Metastases: Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Nov 28, 2014
P=N/A, N=293, Completed, Sponsor: SCRI Development Innovations, LLC
Trial primary completion date: Oct 2014 --> Jan 2015 Active, not recruiting --> Completed | N=450 --> 293 | Trial primary completion date: Aug 2016 --> Jul 2014
- |||| Trial primary completion date: KRISTINE: A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (clinicaltrials.gov) - Nov 25, 2014
P3, N=432, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | N=450 --> 293 | Trial primary completion date: Aug 2016 --> Jul 2014 Trial primary completion date: Jan 2018 --> Sep 2018
- lumretuzumab (RG7116) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein (clinicaltrials.gov) - Nov 25, 2014
P1, N=40, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jan 2018 --> Sep 2018 Trial primary completion date: Feb 2017 --> Nov 2016
- Perjeta (pertuzumab) / Roche
Enrollment closed, Adverse events: The Efficacy of Acupuncture in Treating Chemotherapy Side Effects in Breast Cancer Patients (clinicaltrials.gov) - Nov 25, 2014
P=N/A, N=66, Active, not recruiting, Sponsor: OhioHealth
Trial primary completion date: Feb 2017 --> Nov 2016 Recruiting --> Active, not recruiting
- ||||| Biomarker, New P2 trial, MSi-H Biomarker, PD(L)-1 Biomarker, Metastases: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Nov 14, 2014
P2, N=1680, Not yet recruiting, Sponsor: Hoffmann-La Roche
- lumretuzumab (RG7116) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein (clinicaltrials.gov) - Nov 12, 2014
P1, N=40, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2016 --> Feb 2017
- |||| Trial primary completion date: KRISTINE: A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (clinicaltrials.gov) - Nov 4, 2014
P3, N=432, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Nov 2016 --> Feb 2017 Trial primary completion date: Sep 2018 --> Jan 2018
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: PERTAIN: A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer (clinicaltrials.gov) - Oct 22, 2014
P2, N=250, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Sep 2018 --> Jan 2018 Trial primary completion date: Nov 2016 --> May 2016
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: PERTAIN: A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer (clinicaltrials.gov) - Oct 17, 2014
P2, N=250, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Nov 2016 --> May 2016 Trial primary completion date: May 2016 --> Nov 2016
- ||| Perjeta (pertuzumab) / Roche
Clinical: Observational Study of Pertuzumab Safety in Participants With Breast Cancer (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=3000, Not yet recruiting, Sponsor: Hoffmann-La Roche
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Combination therapy, Metastases: A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer (clinicaltrials.gov) - Oct 17, 2014
P2, N=189, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: May 2016 --> Nov 2016 Recruiting --> Active, not recruiting
- Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: SOLTI-Opti-HER: Study of Neoadjuvant Myocet (clinicaltrials.gov) - Oct 15, 2014
P2, N=83, Recruiting, Sponsor: SOLTI Breast Cancer Research Group
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, Metastases: Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy (clinicaltrials.gov) - Sep 30, 2014
P2, N=45, Not yet recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- Biomarker, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Sep 22, 2014
P2, N=800, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
Active, not recruiting --> Recruiting Trial primary completion date: Feb 2014 --> Sep 2015
- Avastin (bevacizumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Metastases: Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers (clinicaltrials.gov) - Sep 12, 2014
P2, N=43, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Trial primary completion date: Feb 2014 --> Sep 2015 Trial primary completion date: Jun 2014 --> Feb 2015
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Metastases: Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer (clinicaltrials.gov) - Sep 12, 2014
P2, N=69, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial primary completion date: Jun 2014 --> Feb 2015 Recruiting --> Active, not recruiting
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Metastases: Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer (clinicaltrials.gov) - Sep 8, 2014
P1/2, N=46, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, Metastases: Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer (clinicaltrials.gov) - Aug 29, 2014
P2, N=200, Not yet recruiting, Sponsor: US Oncology Research
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Metastases: PETRA: Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC) (clinicaltrials.gov) - Aug 27, 2014
P1, N=30, Recruiting, Sponsor: Ontario Clinical Oncology Group (OCOG)
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2014 --> Dec 2015
- lumretuzumab (RG7116) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein (clinicaltrials.gov) - Aug 21, 2014
P1, N=40, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Sep 2015 --> Nov 2016
- || Trial primary completion date: MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I (clinicaltrials.gov) - Aug 4, 2014
P4, N=226, Recruiting, Sponsor: Agendia
Trial primary completion date: Sep 2015 --> Nov 2016 Trial primary completion date: Dec 2013 --> Dec 2015
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: INNOVATION: Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Aug 1, 2014
P2, N=220, Not yet recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib (clinicaltrials.gov) - Jul 30, 2014
P1, N=40, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Dec 2013 --> Dec 2015 Trial primary completion date: May 2014 --> May 2015
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial initiation date, Combination therapy, Metastases: NeoSphere: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer. (clinicaltrials.gov) - Jul 30, 2014
P2, N=417, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: May 2014 --> May 2015 Initiation date: Dec 2007 --> Jun 2006
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Metastases: Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Jul 30, 2014
P=N/A, N=450, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Initiation date: Dec 2007 --> Jun 2006 Recruiting --> Active, not recruiting
- || Trial primary completion date, Tumor mutational burden, PD(L)-1 Biomarker, Metastases: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jul 23, 2014
P2a, N=500, Recruiting, Sponsor: Genentech
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2019 --> Jan 2020
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: NSABP Biospecimen Discovery Project (clinicaltrials.gov) - Jul 21, 2014
P=N/A, N=50, Recruiting, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Trial primary completion date: Aug 2019 --> Jan 2020 Trial primary completion date: Mar 2014 --> Aug 2014
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: PERTAIN: A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer (clinicaltrials.gov) - Jul 15, 2014
P2, N=250, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2014 --> Aug 2014 Trial primary completion date: May 2015 --> May 2016
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed: APHINITY: A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (clinicaltrials.gov) - Jul 15, 2014
P3, N=4808, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: May 2015 --> May 2016 Recruiting --> Active, not recruiting
- Trial primary completion date: Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy (clinicaltrials.gov) - Jul 14, 2014
P2, N=20, Recruiting, Sponsor: Columbia University
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2013 --> Oct 2015
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial initiation date, Combination therapy, Metastases: BERENICE: A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (clinicaltrials.gov) - Jul 1, 2014
P2, N=400, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Oct 2013 --> Oct 2015 Initiation date: Sep 2014 --> Jun 2014
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Trial initiation date, Combination therapy, Metastases: BERENICE: A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (clinicaltrials.gov) - Jul 1, 2014
P2, N=400, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Sep 2014 --> Jun 2014 Not yet recruiting --> Recruiting | Initiation date: Sep 2014 --> Jun 2014
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: PERTAIN: A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer (clinicaltrials.gov) - Jun 29, 2014
P2, N=250, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting | Initiation date: Sep 2014 --> Jun 2014 Trial primary completion date: Jun 2016 --> May 2016
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Combination therapy, Metastases: A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer (clinicaltrials.gov) - Jun 29, 2014
P2, N=213, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jun 2016 --> May 2016 Recruiting --> Active, not recruiting
- |||||| Enrollment open: KRISTINE: A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (clinicaltrials.gov) - Jun 27, 2014
P3, N=432, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: APHINITY: A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (clinicaltrials.gov) - Jun 27, 2014
P3, N=4800, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Metastases: PETRA: Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC) (clinicaltrials.gov) - Jun 18, 2014
P1, N=30, Recruiting, Sponsor: Ontario Clinical Oncology Group (OCOG)
Active, not recruiting --> Recruiting Trial primary completion date: Aug 2014 --> Dec 2014
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial initiation date, Metastases: Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer (clinicaltrials.gov) - Jun 17, 2014
P1/2, N=46, Not yet recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Aug 2014 --> Dec 2014 Initiation date: May 2014 --> Sep 2014
- || Trial primary completion date, Tumor mutational burden, PD(L)-1 Biomarker, Metastases: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (clinicaltrials.gov) - May 18, 2014
P2a, N=500, Recruiting, Sponsor: Genentech
Initiation date: May 2014 --> Sep 2014 Trial primary completion date: Jan 2020 --> Aug 2019
- || Trial completion date, Tumor mutational burden, PD(L)-1 Biomarker, Metastases: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (clinicaltrials.gov) - May 18, 2014
P2a, N=500, Recruiting, Sponsor: Genentech
Trial primary completion date: Jan 2020 --> Aug 2019 Trial completion date: Jan 2020 --> Aug 2019